Company VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-16 pm EST			5-day change	1st Jan Change
0.5668 ^USD	-0.04%		-0.51%	-2.29%

Dec. 18	RTW Biotech Opportunities announces new investment in Yarrow Bioscience	RE
Dec. 17	VYNE Therapeutics Inc., Yarrow Bioscience, Inc. - M&A Call

Business description: VYNE Therapeutics Inc.

VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.

Number of employees: 13

Sales by Activity: VYNE Therapeutics Inc.

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Pharmaceuticals	20.99M	14.76M	477K	424K	501K

See all business segments

Executive Committee: VYNE Therapeutics Inc.

Manager	Title	Age	Since
David Domzalski CEO	Chief Executive Officer	60	2020-02-29
Tyler Zeronda DFI	Director of Finance/CFO	40	-
Iain Stuart CTO	Chief Tech/Sci/R&D Officer	53	2020-02-29
Mutya Harsch LAW	General Counsel	52	2020-02-29

See VYNE THERAPEUTICS INC. governance

Composition of the Board of Directors: VYNE Therapeutics Inc.

Director	Title	Age	Since
David Domzalski BRD	Director/Board Member	60	2020-02-29
Sharon Barbari BRD	Director/Board Member	72	2020-02-29
Steven Basta BRD	Director/Board Member	61	2014-12-31
Elisabeth Little Sandoval BRD	Director/Board Member	64	2019-02-28
Pat LePore BRD	Director/Board Member	71	2020-09-09

Composition of the Board of Directors

Shareholders: VYNE Therapeutics Inc.

Name	Equities	%	Valuation
Access Industries, Inc. (New York) 3.354 %	1,116,585	3.354 %	647 619 $
Baker Bros. Advisors LP 2.558 %	851,353	2.558 %	493 785 $
DSC Advisors LP 2.092 %	696,465	2.092 %	403 950 $
Acorn Capital Advisors LLC 1.762 %	586,572	1.762 %	340 212 $
Shay Capital LLC 1.48 %	492,577	1.48 %	285 695 $

List of VYNE THERAPEUTICS INC. shareholders

Company details: VYNE Therapeutics Inc.

VYNE Therapeutics, Inc.

685 Route 202/206 North

08807, Bridgewater

http://www.vynetherapeutics.com

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VYNE THERAPEUTICS INC.	-0.04%	-0.51%	-78.03%	-88.24%	18.87M
ARGENX SE	-0.49%	0.00%	+8.21%	+89.09%	49.24B
WUXI APPTEC CO., LTD.	+0.71%	+5.27%	+94.84%	+6.23%	44.64B
INSMED INCORPORATED	+1.35%	-8.27%	+121.88%	+729.92%	34.43B
BIONTECH SE	+2.76%	+9.16%	-3.33%	-24.85%	27.35B
WUXI BIOLOGICS (CAYMAN) INC.	-0.60%	+7.34%	+124.24%	-46.17%	21.08B
GENMAB A/S	+0.97%	+0.14%	+43.23%	-21.74%	20.89B
AKESO, INC.	-0.74%	-5.17%	+112.47%	+148.97%	14.29B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.72%	-0.55%	+196.50%	-	14.17B
SUMMIT THERAPEUTICS INC.	-1.33%	-13.41%	-6.32%	+255.00%	13.14B
Average	+0.33%	-0.56%	+61.37%	+116.47%	23.92B
Weighted average by Cap.	+0.50%	+0.50%	+69.26%	+147.34%